) posted a 10% rise in adjusted earnings per share to 55 cents in
the fourth quarter of its fiscal year from 50 cents in the
comparable quarter of fiscal 2012. However, earnings per share
missed the Zacks Consensus Estimate by a penny. Adjusted net
earnings rose 9% to $121 million from $111 million in the
Revenues in the quarter fell 6.0% to $903 million, lagging the
Zacks Consensus Estimate of $914 million. The decrease was driven
by a fall in Medical Systems revenues, partially offset by strong
revenue growth in the Procedural Solutions segment.
Adjusted operating income for the quarter grew 4% to $189 million
from $182 million a year ago. Adjusted operating margin went up
200 basis points (bps) to 20.9% from 18.9% in the fourth quarter
of fiscal 2012.
Revenues from the
went down 12% to $592 million on both a reported and constant
currency basis from the prior year period. Adjusted segment
profit slipped 4% to $136 million due to lower revenues,
partially offset by improvements in gross margin and operating
rose 7% to $311 million, driven by continued boost from its
clinically differentiated products in specialty disposables.
Adjusted segment profit grew 29% to $53 million due to higher
sales and margin improvement across all business lines.
Fiscal 2013 Results
CareFusion reported a 9% rise in adjusted earnings per share to
$2.12 in the year from $1.95 a year ago while net earnings
improved 8% to $475 million from $441 million a year ago.
Revenues fell marginally by 1% to $3.55 billion in the fiscal
Adjusted operating income for the quarter grew 8% to $739 million
from $687 million a year ago. Adjusted operating margin increased
170 bps to 20.8% from 19.1% in fiscal 2012.
CFN's board of directors approved a two-year $750 million share
repurchase program, after completing their previous $500 million
authorization in Jun this year. Under the previous authorization,
the company repurchased approximately 11.4 million shares for
$400 million in fiscal 2013.
Fiscal 2014 Outlook
For fiscal 2014, CareFusion expects revenues to grow between 1%
and 4% on a constant currency basis. Adjusted earnings are
expected to be in the range of $2.30 to $2.40 per share.
The guidance is based on an assumed weighted average outstanding
share count of approximately 215 million, which includes the
impact of expected share repurchases during fiscal 2014.
CareFusion is a global corporation serving the health care
industry with products and services that help hospitals
measurably improve the safety and quality of care. Currently, the
stock retains a Zacks Rank #3 (Hold).
Other stocks that are performing well in the medical products
), both with a Zacks Rank #1 (Strong Buy), and
) with a Zacks Rank #2 (Buy).
ADVAXIS INC (ADXS): Free Stock Analysis
ALERE INC (ALR): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
HANGER ORTHOPED (HGR): Free Stock Analysis
To read this article on Zacks.com click here.